Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients
NCT ID: NCT05679648
Last Updated: 2023-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2023-06-01
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating Atherosclerosis In Seronegative Spondyloarthropathy
NCT04891783
Musculoskeletal Ultrasound with Elastography in the Evaluation of Muscle State in Rheumatoid Arthritis Patients
NCT06620484
Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
NCT00394238
Ultrasonography as a Biomarker in Early Rheumatoid Arthritis
NCT00781989
Assessment of 14-3-3 η (Eta) Protein Antibodies in the Serum of Rheumatoid Arthritis Patients and Its Relation to Atherosclerosis.
NCT04937140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rheumatoid arthritis patients
ultrasonography
studying degree of steatosis
control
ultrasonography
studying degree of steatosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ultrasonography
studying degree of steatosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age≥18 years
Exclusion Criteria
* Receiving hepatotoxic drugs other than RA-specific drugs.
* Alcohol abuse (i30 g/day in men and ⩾20 g/day in women).
* Diagnosis of Wilson's disease, α1-antitrypsin deficiency or hemochromatosis.
* Autoimmune liver disease.
* Cancer.
* Pregnancy.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Hamed
Lecturer
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-22-11-17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.